In collaboration with the European project SYNBEE, which strives to enhance entrepreneurship in synthetic biology across Europe, we are calling on researchers and entrepreneurs with disruptive synthetic biology solutions that address our planet’s most pressing environmental and sustainability challenges.
The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.
eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.
The European project will enhance the commercial potential of one of today’s most disruptive fields
Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.
Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology and IT and is a key player in the DNA data storage space. Its ambition is to help meet the climate challenge posed by data centers.
This expands eureKARE’s synthetic biology studio network – each with a different theme – in Europe’s innovation hotspots. The Monaco studio will be the network’s hub for climate change-focused innovation.
[Translated in English from a tribune published in the French newspaper L’Opinion on October 27th 2022].
The health crisis has demonstrated with a brutality that has shocked – and sometimes bruised – many of our fellow citizens: Europe, and in particular France, has lost control of the supply chain of its health products, particularly of some of its Medicines of Major Therapeutic Interest (MMTI).
In his introductory speech, His Serene Highness Prince Albert II of Monaco stated: “I am especially pleased that the Principality of Monaco is able to welcome your work, support it and contribute to its success. I also welcome the dialogue that has been established between eureKARE and the Scientific Center of Monaco, in particular the opportunity to host one of your studios on its premises, like those you have already set up in various scientific centers across Europe”.
Organized by eureKARE and the Centre Scientifique de Monaco (CMS), SynBio Day, a conference about synthetic biology, took place in mid-October in the Principality of Monaco, giving an opportunity to discuss advances in technologies with tremendous potential.
Luxembourg | France | Belgium
Subscribe to our news to keep in touch
